512 related articles for article (PubMed ID: 15836010)
21. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.
Einarson TR; Pudas H; Zilbershtein R; Jensen R; Vicente C; Piwko C; Hemels ME
J Med Econ; 2013 Sep; 16(9):1096-105. PubMed ID: 23844621
[TBL] [Abstract][Full Text] [Related]
22. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
Haycox A
Pharmacoeconomics; 2005; 23 Suppl 1():3-16. PubMed ID: 16416758
[TBL] [Abstract][Full Text] [Related]
23. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.
Edwards NC; Pesa J; Meletiche DM; Engelhart L; Thompson AK; Sherr J; Dirani R
Curr Med Res Opin; 2008 Dec; 24(12):3341-55. PubMed ID: 18954497
[TBL] [Abstract][Full Text] [Related]
24. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Bounthavong M; Okamoto MP
J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
Obradovic M; Mrhar A; Kos M
Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
[TBL] [Abstract][Full Text] [Related]
28. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Einarson TR; Pudas H; Goswami P; van Impe K; Bereza BG
J Med Econ; 2016; 19(2):111-20. PubMed ID: 26414966
[TBL] [Abstract][Full Text] [Related]
29. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
30. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.
Einarson TR; Zilbershtein R; Skoupá J; Veselá S; Garg M; Hemels ME
J Med Econ; 2013 Sep; 16(9):1089-95. PubMed ID: 23808900
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
[TBL] [Abstract][Full Text] [Related]
33. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
Achilla E; McCrone P
Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.
Frey S; Linder R; Juckel G; Stargardt T
Eur J Health Econ; 2014 Mar; 15(2):133-42. PubMed ID: 23420082
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.
Yang L; Li M; Tao LB; Zhang M; Nicholl MD; Dong P
Value Health; 2009; 12 Suppl 3():S66-9. PubMed ID: 20586985
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
[TBL] [Abstract][Full Text] [Related]
37. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
[TBL] [Abstract][Full Text] [Related]
38. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
39. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
Bartkó G; Fehér L
Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
